More on DSNKY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $18.00 |
|
|||
| Open | $17.89 | ||||
| 52 Wk High | $26.24 | ||||
| 52 Wk Low | $18.86 | ||||
| Day High | $18.30 | ||||
| Day Low | $17.80 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 280,733 | ||||
- GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
- Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
- ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
- Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,900 at Citi
- DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
- DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
- UBS Starts Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) at Neutral
- Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
- Daiichi Sankyo opens Toronto headquarters to fuel Canadian oncology growth
- Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Entities mentioned with DSNKY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Deutsche Bank | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
